Elias H Klein

US Patent:

6833060, Dec 21, 2004

Filed:

May 7, 2001

Appl. No.:

09/850540

Inventors:

George Harding - Louisville KY
Elias Klein - Louisville KY
Jon Klein - Louisville KY

Assignee:

University of Louisville Research Foundation, Inc. - Louisville KY

International Classification:

G01N 27453

US Classification:

204466, 204456, 204464, 204616, 204606, 204614

Abstract:

The present invention relates generally to the electrophoretic separation of biomolecules, including but not limited to proteins, peptides, DNA and RNA. The methods of this invention are particularly useful when applied to two-dimensional gel electrophoresis.

US Patent:

7550584, Jun 23, 2009

Filed:

Mar 27, 2006

Appl. No.:

11/390986

Inventors:

Arun K. Bahl - Cornelius NC, US
Sharon V. Vercellotti - Covington LA, US
John R. Vercellotti - Covington LA, US
Elias Klein - Louisville KY, US

Assignee:

Immudyne, Inc. - Mt. Kisco NY

International Classification:

C07H 1/06
C07H 1/08

US Classification:

536127, 5361231, 536124

Abstract:

The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are administered so as to enhance the development of osteoblasts and the inhibition of the development and recruitment of osteoclasts. The inhibition of the recruitment and development of osteoclasts, coupled with the enhancement of osteoblast maturation by beta glucans leads to decreased bone resorption and increased bone formation, making beta glucans ideal agents for the treatment of osteoporosis and other bone resorption diseases.

US Patent:

7777027, Aug 17, 2010

Filed:

Apr 14, 2008

Appl. No.:

12/102356

Inventors:

Arun K. Bahl - Cornelius NC, US
Sharon V. Vercellotti - Covington LA, US
John R. Vercellotti - Covington LA, US
Elias Klein - Louisville KY, US

Assignee:

Immudyne, Inc. - Mt. Kisco NY

International Classification:

C07H 1/00

US Classification:

53612312, 536 552, 536 553, 5361231

Abstract:

The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are administered so as to enhance the development of osteoblasts and the inhibition of the development and recruitment of osteoclasts. The inhibition of the recruitment and development of osteoclasts, coupled with the enhancement of osteoblast maturation by beta glucans leads to decreased bone resorption and increased bone formation, making beta glucans ideal agents for the treatment of osteoporosis and other bone resorption diseases.

US Patent:

20090258379, Oct 15, 2009

Filed:

Apr 26, 2007

Appl. No.:

12/298467

Inventors:

Jon Klein - Louisville KY, US
Elias Klein - Louisville KY, US
Michael Merchant - Louisville KY, US

Assignee:

UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. - Louisville KY

International Classification:

G01N 33/00
C12N 1/00
C12Q 1/00
C07K 1/14

US Classification:

435 792, 4353171, 435 4, 530344

Abstract:

Methods of isolating membrane vesicles from a biological fluid sample are provided. In some embodiments, the methods comprise providing a biological fluid sample comprising membrane vesicles; filtering the biological fluid sample through a filtration module comprising a filter having an average pore diameter of between about 0.01 um and about 0.15 um; and collecting from the filtration module a retentate comprising the membrane vesicles, thereby isolating the membrane vesicles from the biological fluid sample.

US Patent:

57669082, Jun 16, 1998

Filed:

Jan 3, 1997

Appl. No.:

8/778689

Inventors:

Elias Klein - Louisville KY
Donald H. Yeager - Louisville KY

Assignee:

Akzo Nobel NV - Arnhem

International Classification:

C12N 1112
G01N 33544
C07K 1706
C07K 1712

US Classification:

435179

Abstract:

An affinity support is provided containing a high flux semipermeable hydrogel membrane surface-modified with an affinity ligand, such as a protein which may be an antibody or enzyme, or a cell receptor complement, useful for affinity separation of biological macromolecules, including insoluble proteins, cells, and cell fragments, from solution. The exclusion limit (molecular weight cut-off) of the matrix is selected to substantially restrict immobilized protein or other ligand to the surface thereof for maximization of available ligand binding capacity. The exclusion limit is also selected to permit reagent(s) used for the matrix/ligand linkage to penetrate into and form covalent bonds with the membrane on the interior surfaces of the membrane for optimizing packing densities of the affinity ligand exterior to the membrane. By this substantially complete orientation of affinity ligand between affinity matrix and solution interface, the recognition sites of the proteins or other ligands are maximally available to complementary molecules or cells bearing complementary determinants for complexing therewith.

US Patent:

59118806, Jun 15, 1999

Filed:

Dec 15, 1995

Appl. No.:

8/573085

Inventors:

Elias Klein - Louisville KY
Natarajan Balachander - Sunnyvale CA

Assignee:

Research Corporation Technologies, Inc. - Tucson AZ

International Classification:

B01D 3900

US Classification:

21050041

Abstract:

A water wettable permselective membrane for use in hemodialysis, ultrafiltration and microfiltration applications and a device containing the same are provided. The membrane having the above properties comprises a hydrophobic-base polymer, such as a polysulfone or polyethersulfone polymer, and a block copolymer additive wherein one of the blocks of the copolymer additive is a hydrophilic polymer and the other block is a hydrophobic polymer that is analogous in structure to the hydrophobic-base polymer.

US Patent:

58694447, Feb 9, 1999

Filed:

May 15, 1991

Appl. No.:

7/701547

Inventors:

Elias Klein - Louisville KY

Assignee:

Research Corporation Technologies, Inc. - Tucson AZ

International Classification:

A01N 3718
A23C 912
C12P 2106

US Classification:

514 2

Abstract:

This invention relates to a peritoneal dialysis solution which comprises as an osmotically active agent an osmotically effective amount of a mixture of peptides, the mixture consisting substantially of peptides having a molecular weight of about 300 to about 2000 daltons, and an equivalent weight between about 150 to about 1500.

US Patent:

50396099, Aug 13, 1991

Filed:

Apr 18, 1988

Appl. No.:

7/182708

Inventors:

Elias Klein - Louisville KY

Assignee:

Research Technologies, Inc. - Tucson AZ

International Classification:

C12P 2106
C07K 112
C07K 1506

US Classification:

435 681

Abstract:

This invention relates to a peritoneal dialysis solution which comprises as an osmotically active agent an osmotically effective amount of a mixture of peptides, the mixture consisting substantially of peptides having a molecular weight of about 300 to about 2000 daltons, and an equivalent weight between about 150 to about 1500.